绿康生化股份有限公司 2025年度业绩预告

Core Viewpoint - The company, *ST Green Health, is expected to report a negative net profit for the fiscal year 2025, marking the first accounting year after the implementation of financial delisting risk warning on its stock [1][10]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025, with an anticipated net profit being negative [1]. - The company has completed a significant asset restructuring, transferring 100% equity of three subsidiaries to another company, which will affect the financial results [2]. Group 2: Communication with Auditors - The company has communicated with its auditing firm regarding the performance forecast, and there are no significant disagreements as of the announcement date [3]. Group 3: Reasons for Performance Changes - The main reason for the performance change is the separation of the loss-making photovoltaic film business, which will no longer be included in the consolidated financial statements [4]. - Despite the expected loss, the veterinary medicine business has seen revenue growth, primarily from higher-margin products, leading to an overall improvement in gross margin compared to 2024 [4]. Group 4: Risk of Delisting - The company reported a negative net asset value of -24,536,065.37 yuan as of the end of 2024, triggering a delisting risk warning [10][14]. - The net profits attributable to shareholders for 2022, 2023, and 2024 were -121,938,109.79 yuan, -221,817,878.58 yuan, and -444,864,018.29 yuan respectively, indicating a continuous decline [11][14]. - If the company’s financial indicators trigger delisting rules again in 2025, the stock may face termination of listing [24]. Group 5: Audit Progress - The auditing firm, Lixin, has been conducting the 2025 annual audit since November 2025, and there are no major disagreements on significant accounting treatments or key audit matters [25][26]. - The company is actively progressing with the preparation and auditing of the 2025 annual report [25].